Insmed says to pursue breakthrough therapy designation for Arikayce in the U.S. Says seeking the "most expeditious path forward" for Arikayce in the EU. Doctors involved in the trial says saw "encouraging" signs in trial, and the company said it is "encouraged" by the achievement of culture conversion in the Phase 2 trial. Comments from the company's conference call discussing results from its U.S. phase 2 clinical trial for treatment resistant nontuberculous mycobacteria lung infections.
Insmed personnel strong, says Piper Jaffray After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.